Combined Radioimmunotherapy and Chemotherapy of Breast Tumors with Y-90-Labeled Anti-Her2 and Anti-CEA Antibodies with Taxol-Reference-Cited by-同舟云学术

Combined Radioimmunotherapy and Chemotherapy of Breast Tumors with Y-90-Labeled Anti-Her2 and Anti-CEA Antibodies with Taxol

Published:2005-08-26 Issue:5 Volume:16 Page:1117-1125
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Crow Desiree M.¹,Williams Lawrence¹,Colcher David¹,Wong Jeffrey Y. C.¹,Raubitschek Andrew¹,Shively John E.¹

Affiliation:

1. Department of Radioimmunotherapy, Division of Radiation Oncology, City of Hope National Medical Center, Duarte, California 91010, Division of Radiology, City of Hope National Medical Center, Duarte, California 91010, and Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/bc0500948

Reference40 articles.

1. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.Cancer Res. 58, 2825−2831.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Radioimmunodetection of Carcinomas with a Re-injection of Monoclonal Antibodies after Formation of Anti-mouse Antibodies;Current Pharmaceutical Design;2023-05

2. Antibodies as Vectors for Radiopharmaceutical Therapy;Radiopharmaceutical Therapy;2023

3. Herceptin-Conjugated DOX-Fe₃O₄/P(NIPAM-AA-MAPEG) Nanogel System for HER2-Targeted Breast Cancer Treatment and Magnetic Resonance Imaging;ACS Applied Materials & Interfaces;2022-04-04

4. Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study;Nuclear Medicine Communications;2021-08-17

5. Perspectives on metals-based radioimmunotherapy (RIT): moving forward;Theranostics;2021